Vera Therapeutics Inc (VERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has a cash flow conversion efficiency ratio of -0.213x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-106.50 Million) by net assets ($499.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vera Therapeutics Inc (VERA) market capitalisation for the company's overall valuation and market capitalisation.
Vera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vera Therapeutics Inc ranked by their cash flow conversion efficiency. See Vera Therapeutics Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SoundHound AI Inc
NASDAQ:SOUN
|
-0.057x |
|
Angang Steel Co Ltd Class A
SHE:000898
|
0.036x |
|
Sinda Ltd.
NYSE:SIND
|
-0.291x |
|
Western Metal Materials Co Ltd
SHE:002149
|
0.000x |
|
Embotelladora Andina S.A
F:AKOB
|
0.113x |
|
United Natural Foods Inc
NYSE:UNFI
|
-0.025x |
|
Maple Leaf Foods Inc.
TO:MFI
|
0.044x |
|
Korea Kolmar
KO:161890
|
0.036x |
Annual Cash Flow Conversion Efficiency for Vera Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2025. View VERA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $604.52 Million | $-241.10 Million | -0.399x | -70.92% |
| 2024-12-31 | $577.15 Million | $-134.68 Million | -0.233x | +74.26% |
| 2023-12-31 | $101.69 Million | $-92.18 Million | -0.907x | -3.14% |
| 2022-12-31 | $76.91 Million | $-67.60 Million | -0.879x | -158.00% |
| 2021-12-31 | $69.59 Million | $-23.71 Million | -0.341x | -187.44% |
| 2020-12-31 | $-89.35 Million | $-34.81 Million | 0.390x | +38.39% |
| 2019-12-31 | $-36.55 Million | $-10.29 Million | 0.282x | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more